NEWS

Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Tech...

NASHVILLE, Tenn., (December 23, 2021) – Today, Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.

Incidental Right MCA Aneurysm

X-Technology Surface Treatment

Subdural hematoma: embolize or operate ?

Growing fusiform posterior cerebral artery aneurysm

Treatment of Intracranial Aneurysms with Surpass Evolve

New Technologies for Stroke Treatment

Aspiration in M1 occlusion in a patient with low NIHSS

BA stenosis angioplasty using laser cut stent

Largest real-world Flow Diverter study verifies safety and efficacy for...

November 16, 2021, Bochum, Germany. The authors of the Diversion-p64  study 1 conclude that phenox’ p64 Flow Modulation Device has a high efficacy and demonstrates one of the lowest rates of morbidity-mortality compared to similar studies. The trial represents the largest prospective study on flow diversion to date. With 420 patients enrolled in 26 centres across 10 countries, the results provide strong evidence for maximized flow modulation effect from the 64-wire braid design of the p64 device for treating intracranial aneurysms.